ENTPD1 and ovarian cancer: Many studies have demonstrated that the adenosinergic pathway contributes to immunosuppression in the TME of ovarian cancer.77 Clinically, the enhanced expression level of CD73 in the tumor tissue predicts a poor prognosis in patients with ovarian carcinoma.78 The tumor cells from the ovarian cancer ascites express functional CD39 and CD73, which promote the generation of adenosine.79 Moreover, the macrophages derived from the malignant ascites exhibit enhanced expression of CD39 and CD73.56 These results suggest that the adenosinergic pathway is activated in the malignant ascites.